Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group: Hematological oncology

G.M. Rigolin, F. Cavazzini, A. Piciocchi, V. Arena, A. Visentin, G. Reda, G. Zamprogna, F. Cibien, O. Vitagliano, M. Coscia, L. Farina, G. Gaidano, R. Murru, M. Varettoni, R. Paolini, P. Sportoletti, D. Pietrasanta, A.L. Molinari, F.M. Quaglia, L. LaurentiR. Marasca, M. Marchetti, F.R. Mauro, E. Crea, M. Vignetti, M. Gentile, M. Montillo, R. Foà, A. Cuneo, GIMEMA Group

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)326-335
Number of pages10
JournalHematol Oncol
Issue number3
Publication statusPublished - 2021

Cite this